TRIBUNJATENG.COM, JAKARTA – There are currently 10 candidate vaccine Covid-19 in the world which is currently undergoing the third phase of clinical trials.
This was conveyed by Wiku Adisasmito, Spokesperson for the Covid-19 Task Force (Task Force).
Of the 10 vaccine candidates, Indonesia has signed a joint procurement agreement with two vaccine candidates, namely from Sinovac and Sinopharm.
• After only 2 months of filming the soap opera, Kiki Farrel confided and said farewell
Both are vaccine developed by a Chinese media company.
As for 10 candidate vaccine such are Sinovac, Wuhan Institute of Biological Products or Sinopharm, Janssen Pharmaceutical Companies (Johnson & Johnson Group), and Cansino Biologics Incorporation or Beijing Institute of Biotechnology.
“Then Gamaleya Research Institute, BioNtech or Fosun Pharma Pfizer, University of Oxford or AstraZeneca, Novavax, Moderna or NIAID, Beijing Institute of Biological Products or Sinopharm,” said Wiku in his press statement on the YouTube channel of the Presidential Secretariat, Tuesday (6/10 / 2020).
Candidate vaccine from Sinovac itself is currently undergoing a third phase clinical trial in Bandung, West Java.
The third stage clinical trial was carried out in collaboration between the state-owned medical company PT Bio Farma, Sinovac and a team from Padjadjaran University.
While candidate vaccine from Sinopharm is undergoing its third phase clinical trial in the United Arab Emirates, in collaboration with the G42.
Other than that, Indonesia also establish joint procurement vaccine with a South Korean company, Genexine.
–
